{"id":"https://openalex.org/W4286295647","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.2559","title":"FORTITUDE: Results of a phase 1a study of the novel transgene-armed and tumor-selective vector NG-350A with and without pembrolizumab (pembro).","display_name":"FORTITUDE: Results of a phase 1a study of the novel transgene-armed and tumor-selective vector NG-350A with and without pembrolizumab (pembro).","publication_year":2022,"publication_date":"2022-06-01","ids":{"openalex":"https://openalex.org/W4286295647","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.2559"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2022.40.16_suppl.2559","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.2559","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.2559","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037497042","display_name":"Lee S. Rosen","orcid":"https://orcid.org/0000-0003-2503-6133","observed_orcids":["https://orcid.org/0000-0003-2503-6133"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lee S. Rosen","raw_affiliation_strings":["UCLA Division of Hematology-Oncology, Santa Monica, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA Division of Hematology-Oncology, Santa Monica, CA;","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082517668","display_name":"D. Ross Camidge","orcid":"https://orcid.org/0000-0003-3430-3213","observed_orcids":["https://orcid.org/0000-0003-3430-3213"]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Ross Camidge","raw_affiliation_strings":["University of Colorado Cancer Center, Aurora, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado Cancer Center, Aurora, CO;","institution_ids":["https://openalex.org/I4210134151"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014236598","display_name":"Danny N. Khalil","orcid":"https://orcid.org/0000-0003-4688-0958","observed_orcids":["https://orcid.org/0000-0003-4688-0958"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Danny Khalil","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY;","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037047198","display_name":"Thomas Lillie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Thomas Lillie","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, Middlesex, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, Middlesex, United Kingdom;","institution_ids":["https://openalex.org/I4210102991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035604562","display_name":"Jo Carter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jo Carter","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, United Kingdom;","institution_ids":["https://openalex.org/I4210102991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047201420","display_name":"David Krige","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"David Krige","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, United Kingdom;","institution_ids":["https://openalex.org/I4210102991"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jessica Davies","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jessica Davies","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, United Kingdom;","institution_ids":["https://openalex.org/I4210102991"]}]},{"author_position":"middle","author":{"id":null,"display_name":"David Miles","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"David Miles","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, United Kingdom;","institution_ids":["https://openalex.org/I4210102991"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Minesh Patel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Minesh Patel","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, United Kingdom;","institution_ids":["https://openalex.org/I4210102991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062492014","display_name":"Vladimir Evilevitch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Vladimir Evilevitch","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, United Kingdom;","institution_ids":["https://openalex.org/I4210102991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032720171","display_name":"Isabel Prieto Gonz\u00e1lez-Albo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Isabel Prieto Gonz\u00e1lez-Albo","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, United Kingdom;","institution_ids":["https://openalex.org/I4210102991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048180481","display_name":"BRIAN R. CHAMPION","orcid":"https://orcid.org/0000-0003-3860-9842","observed_orcids":["https://orcid.org/0000-0003-3860-9842"]},"institutions":[{"id":"https://openalex.org/I4210102991","display_name":"PsiOxus Therapeutics (United Kingdom)","ror":"https://ror.org/019g16n05","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Brian Champion","raw_affiliation_strings":["PsiOxus Therapeutics Ltd, Abingdon, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PsiOxus Therapeutics Ltd, Abingdon, United Kingdom;","institution_ids":["https://openalex.org/I4210102991"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005436649","display_name":"Aung Naing","orcid":"https://orcid.org/0000-0002-4803-8513","observed_orcids":["https://orcid.org/0000-0002-4803-8513"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aung Naing","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"40","issue":"16_suppl","first_page":"2559","last_page":"2559"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","score":0.9320999979972839,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","score":0.9320999979972839,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.05460000038146973,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.009800000116229057,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-cd40-antibody","display_name":"anti-CD40 antibody","score":0.8149999976158142},{"id":"https://openalex.org/keywords/adenovirus-vectors","display_name":"adenoviral vector","score":0.8370000123977661},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9860000014305115},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-combination-therapy","display_name":"immune checkpoint inhibitor combination","score":0.6779999732971191},{"id":"https://openalex.org/keywords/intratumoral-injection","display_name":"intratumoral injection","score":0.6700000166893005},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5820000171661377},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.6690000295639038},{"id":"https://openalex.org/keywords/cytokine-response","display_name":"cytokine response","score":0.6259999871253967},{"id":"https://openalex.org/keywords/il-12","display_name":"IL-12","score":0.7580000162124634},{"id":"https://openalex.org/keywords/interferon-gamma","display_name":"interferon-gamma","score":0.8220000267028809},{"id":"https://openalex.org/keywords/il-17a","display_name":"IL-17A","score":0.9139999747276306},{"id":"https://openalex.org/keywords/first-in-human","display_name":"first-in-human","score":0.43700000643730164}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6477881669998169},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.5038244128227234},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.4952827990055084},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.43422770500183105},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4281112849712372},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4207055866718292},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39917516708374023},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3736233711242676},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.31512558460235596}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2022.40.16_suppl.2559","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.2559","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.2559","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4282977747","https://openalex.org/W3203962580","https://openalex.org/W4282975318","https://openalex.org/W4404052791","https://openalex.org/W4308382086","https://openalex.org/W4286298873","https://openalex.org/W4286293766","https://openalex.org/W2242060213","https://openalex.org/W4380082990","https://openalex.org/W4379336588"],"abstract_inverted_index":{"2559":[0],"Background:":[1],"Stimulating":[2],"CD40":[3,201],"may":[4],"support":[5],"anti-cancer":[6],"immune":[7],"responses;":[8],"however,":[9,226],"on-target":[10],"toxicity":[11],"limits":[12],"systemic":[13,55,200,374,387],"dosing.":[14],"NG-350A":[15,35,77,87,110,164,185,231,263,312,316,335,346,378,398],"is":[16,71,309],"a":[17,26,61,72,403],"tumor-selective":[18],"and":[19,177,194,210,254,352],"blood":[20],"stable":[21,239],"adenoviral":[22],"T-SIGn":[23],"vector":[24],"expressing":[25],"potent":[27],"fully":[28],"human":[29],"IgG":[30],"agonistic":[31],"anti-CD40":[32,41,363,375],"antibody":[33],"(mAb).":[34],"was":[36,90,119,167,186,204,219,338],"designed":[37],"to":[38,42,191,214,319,350,401],"selectively":[39],"deliver":[40],"multiple":[43],"tumor":[44,51,383],"sites":[45],"via":[46],"IV":[47,101,109,142,145,153,157,178,234,262,288,315,347],"delivery,":[48],"driving":[49],"immunological":[50,382],"re-engineering":[52],"while":[53,385],"avoiding":[54,386],"toxicity.":[56,345,388],"We":[57],"report":[58],"results":[59],"from":[60,265],"first-in-human":[62],"trial":[63,391,410],"after":[64,277],"completion":[65],"of":[66,76,98,124,163,184,282,322,329,343,360,397],"enrollment.":[67],"Methods:":[68],"FORTITUDE":[69],"(NCT03852511)":[70],"phase":[73],"1":[74],"study":[75],"\u00b1":[78,165,336],"pembro":[79,112,155,166,337,400],"in":[80,92,216,250,258,279,300,326],"patients":[81,228],"(pts)":[82],"with":[83,170,188,230,245,261,296,303,340,357,373],"metastatic/advanced":[84],"epithelial":[85],"tumors.":[86],"monotherapy":[88],"(mTx)":[89],"dose-escalated":[91],"separate":[93],"intratumoral":[94],"(IT;":[95],"increasing":[96,105],"numbers":[97],"doses)":[99],"or":[100,152],"(one":[102],"cycle;":[103],"three":[104],"dose":[106,140,146,158,179,208,235,289,404],"levels)":[107],"cohorts.":[108],"+":[111,154,313,399],"(200":[113],"mg":[114],"Q3W":[115],"for":[116,311,406],"\u22648":[117],"cycles)":[118],"then":[120],"assessed.":[121],"Results:":[122],"As":[123],"Jan":[125],"2022,":[126],"28":[127],"heavily":[128],"pre-treated":[129],"pts":[130,259,284],"had":[131],"received":[132],"NG-350A,":[133],"either":[134],"as":[135],"IT":[136,176,297],"mTx":[137,143,232,264,348],"(n=9;":[138],"two":[139],"levels),":[141],"(n=16;":[144],"levels":[147,274],"1,":[148],"3":[149],"&":[150],"4)":[151],"(n=3;":[156],"level":[159,209,236,405],"2).":[160],"The":[161,181],"MTD":[162],"not":[168,242,294],"reached,":[169],"no":[171,341],"DLTs":[172],"at":[173,206,233,271,286],"the":[174,211,280,320,358,361],"highest":[175],"levels.":[180,290],"safety":[182],"profile":[183],"consistent":[187,356],"acute":[189],"reactions":[190],"viral":[192],"particles":[193],"asymptomatic":[195],"aPTT":[196],"prolongations":[197],"(Table).":[198],"No":[199,221],"transgene":[202],"protein":[203],"detected":[205,257],"any":[207],"only":[212],"SAE":[213],"occur":[215,295],">1":[217],"pt":[218],"pneumonia.":[220],"objective":[222],"responses":[223,292,355],"were":[224,256,269,331,368],"observed;":[225],"3/6":[227],"treated":[229,260,285],"4":[237],"achieved":[238],"disease":[240],"(dose":[241],"yet":[243],"tested":[244],"pembro).":[246],"Dose-dependent":[247],"specific":[248,351],"increases":[249],"serum":[251],"IL-12,":[252],"IFN\u03b3":[253],"IL-17a":[255],"\u0303Wk":[266],"2.":[267],"Increases":[268],"sustained":[270,353],"\u22655x":[272],"baseline":[273],"7":[275],"wks":[276],"dosing":[278,298],"majority":[281],"evaluable":[283],"higher":[287,370],"These":[291],"did":[293],"(or":[299],"prior":[301],"studies":[302],"an":[304],"unarmed":[305],"vector);":[306],"further":[307,390],"follow-up":[308],"ongoing":[310],"pembro.":[314],"also":[317],"led":[318,349],"expansion":[321],"T":[323],"cell":[324],"clones":[325],"blood;":[327],"most":[328],"these":[330],"newly":[332],"detected.":[333],"Conclusions:":[334],"well-tolerated,":[339],"evidence":[342],"CD40-related":[344],"cytokine":[354,366],"MoA":[359],"encoded":[362],"Ab.":[364],"Peak":[365],"elevations":[367],"typically":[369],"than":[371],"reported":[372],"Abs,":[376],"suggesting":[377],"can":[379],"drive":[380],"local":[381],"changes":[384],"A":[389],"(FORTIFY,":[392],"NCT05165433)":[393],"will":[394],"continue":[395],"dose-escalation":[396],"identify":[402],"efficacy":[407],"assessments.":[408],"Clinical":[409],"information:":[411],"NCT03852511.":[412],"[Table:":[413],"see":[414],"text]":[415]},"counts_by_year":[{"year":2023,"cited_by_count":2}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2022-07-21T00:00:00"}